GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PhaseRx Inc (OTCPK:PZRXQ) » Definitions » Operating Income

PhaseRx (PhaseRx) Operating Income : $-13.04 Mil (TTM As of Sep. 2017)


View and export this data going back to 2016. Start your Free Trial

What is PhaseRx Operating Income?

PhaseRx's Operating Income for the three months ended in Sep. 2017 was $-2.54 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2017 was $-13.04 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. PhaseRx's Operating Income for the three months ended in Sep. 2017 was $-2.54 Mil. PhaseRx's Revenue for the three months ended in Sep. 2017 was $0.00 Mil. Therefore, PhaseRx's Operating Margin % for the quarter that ended in Sep. 2017 was %.

PhaseRx's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. PhaseRx's annualized ROC % for the quarter that ended in Sep. 2017 was -505.11%. PhaseRx's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2017 was -4,600.91%.


PhaseRx Operating Income Historical Data

The historical data trend for PhaseRx's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PhaseRx Operating Income Chart

PhaseRx Annual Data
Trend Dec14 Dec15 Dec16
Operating Income
-5.59 -5.81 -18.33

PhaseRx Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.14 -3.27 -3.92 -3.32 -2.54

PhaseRx Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Sep. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-13.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PhaseRx  (OTCPK:PZRXQ) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

PhaseRx's annualized ROC % for the quarter that ended in Sep. 2017 is calculated as:

ROC % (Q: Sep. 2017 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2017 ) + Invested Capital (Q: Sep. 2017 ))/ count )
=-10.14 * ( 1 - 0% )/( (1.976 + 2.039)/ 2 )
=-10.14/2.0075
=-505.11 %

where

Note: The Operating Income data used here is four times the quarterly (Sep. 2017) data.

2. Joel Greenblatt's definition of Return on Capital:

PhaseRx's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2017 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2017 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2017  Q: Sep. 2017
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-10.076/( ( (0.229 + max(-0.475, 0)) + (0.209 + max(-0.326, 0)) )/ 2 )
=-10.076/( ( 0.229 + 0.209 )/ 2 )
=-10.076/0.219
=-4,600.91 %

where Working Capital is:

Working Capital(Q: Jun. 2017 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.615) - (1.09 + 0 + 0)
=-0.475

Working Capital(Q: Sep. 2017 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0.572) - (0.898 + 0 + 0)
=-0.326

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2017) EBIT data.

3. Operating Income is also linked to Operating Margin %:

PhaseRx's Operating Margin % for the quarter that ended in Sep. 2017 is calculated as:

Operating Margin %=Operating Income (Q: Sep. 2017 )/Revenue (Q: Sep. 2017 )
=-2.535/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


PhaseRx Operating Income Related Terms

Thank you for viewing the detailed overview of PhaseRx's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


PhaseRx (PhaseRx) Business Description

Traded in Other Exchanges
N/A
Address
410 West Harrison Street, Suite 300, Seattle, WA, USA, 98119
PhaseRx Inc is a biopharmaceutical company. It is developing a portfolio of products for the treatment of inherited enzyme deficiencies in the liver using intracellular enzyme replacement therapy, or i-ERT. The approach is enabled by proprietary Hybrid messenger RNA, or mRNA, Technology platform, which allows synthesis of the missing enzyme inside the cell. The product portfolio targets the three urea cycle disorders ornithine transcarbamylase deficiency, or OTCD, argininosuccinate lyase deficiency, or ASL deficiency, and argininosuccinate synthetase deficiency, or ASS1 deficiency.
Executives
Gordon Brandt officer: Chief Medical Officer 410 WEST HARRISON STREET, SEATTLE WA 98119
Paul H Johnson director 3450 MONTE VILLA PARKWAY, BOTHELL WA 98053
Peggy V Phillips director C/O DYNAVAX TECHNOLOGIES CORPORATION, 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710
Michelle Renee Griffin director 19723 NE 65TH LANE, KIRKLAND WA 98033
Brian G Atwood director, 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Schmidt John A Jr director 300 THIRD ST, CAMBRIDGE X1 02142
Steven Gillis director, 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Samuel D Colella 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Robert Nelsen 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Rebecca B Robertson 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Barbara N Lubash 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Donald B Milder 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Charles M Warden 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Side Fund Iii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Venture Capital Iii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104

PhaseRx (PhaseRx) Headlines

From GuruFocus

Stocks Open Higher in Friday Session

By Omar Venerio Omar Venerio 10-13-2017

PhaseRX: The Latest Pick From a Legendary VC Firm

By $$$ Christopher Malcolm 05-24-2016